Skip to main content

Advertisement

Table 2 SVR12 by the different duration of treatment, regimens, genotypes, treatment history, and the presence or absence of cirrhosis

From: Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis

Response SVR12 (N = 1358) Heterogeneity Pb-value Studies
  Total, n/N Rate (95%CI) I2(%) P a   
Overall 1296/1358 96.3 (95.1–97.4) 42 0.08   10
By the different duration of treatment 0.9237  
 12 weeks 394/415 96.2 (92.6–98.8) 41 0.13   6
 24 weeks 52/55 96.6 (82.5–100.0) 65 0.09   2
By regimens 0.8563  
 OBV/PTV/r ± DSV ± RBV 811/850 96.4 (94.8–97.7) 25 0.21   10
 OBV/PTV/r ± RBV 152/159 98.9 (95.3–100.0) 0.0 0.99   3
By genotypes 0.8424  
 1 1025/1076 96.2 (94.8–97.4) 38 0.13   8
 4 149/156 98.8 (95.1–100.0) 0 0.99   3
By treatment history 0.8281  
 TN patients 423/440 96.8 (94.8–98.5) 41 0.15   5
 TE patients 273/285 98.9 (96.4–100.0) 50 0.09   5
By the presence or absence of cirrhosis 0.3887  
 Cirrhosis 218/230 97.8 (94.6–99.8) 43 0.12   6
 Non-cirrhosis 899/935 96.7 (95.3–97.8) 20 0.28   6
  1. *OBV ombitasvir; PTV paritaprevir, r ritonavir, DSV dasabuvir; RBV ribavirin, TN treatment-naive, TE treatment-experienced, CI confidence interval
  2. aTest of heterogeneity
  3. bTest for subgroup differences